Halozyme Therapeutics Inc’s recently made public that its SVP, CHIEF TECHNICAL OFFICER LaBarre Michael J. unloaded Company’s shares for reported $0.54 million on Oct 15 ’24. In the deal valued at $53.75 per share,10,000 shares were sold. As a result of this transaction, LaBarre Michael J. now holds 173,756 shares worth roughly $7.93 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, LaBarre Michael J. sold 10,000 shares, generating $532,590 in total proceeds. Upon selling the shares at $53.26, the SVP, CHIEF TECHNICAL OFFICER now owns 173,756 shares.
Before that, MICHAEL LABARRE bought 10,000 shares. Halozyme Therapeutics Inc shares valued at $532,592 were divested by the Officer at a price of $53.26 per share.
Wells Fargo downgraded its Halozyme Therapeutics Inc [HALO] rating to an Equal weight from a an Overweight in a research note published on October 07, 2024; the price target was increased to $62 from $58. A number of analysts have revised their coverage, including JP Morgan’s analysts, who decreased its forecast for the stock in mid September from “an Overweight” to “a Neutral”. Piper Sandler also remained covering HALO and has decreased its forecast on June 07, 2024 with a “Neutral” recommendation from previously “an Overweight” rating. TD Cowen started covering the stock on February 29, 2024. It rated HALO as “an Outperform”.
Price Performance Review of HALO
On Friday, Halozyme Therapeutics Inc [NASDAQ:HALO] saw its stock fall -15.40% to $45.65. Over the last five days, the stock has lost -25.14%. Halozyme Therapeutics Inc shares have risen nearly 23.51% since the year began. Nevertheless, the stocks have risen 16.04% over the past one year. While a 52-week high of $65.53 was reached on 08/29/24, a 52-week low of $33.15 was recorded on 02/05/24. SMA at 50 days reached $56.04, while 200 days put it at $49.02.
Levels Of Support And Resistance For HALO Stock
The 24-hour chart illustrates a support level at 44.30, which if violated will result in even more drops to 42.96. On the upside, there is a resistance level at 48.32. A further resistance level may holdings at 50.99. The Relative Strength Index (RSI) on the 14-day chart is 30.20, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.43, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 99.85%. Stochastics %K at 35.97% indicates the stock is a holding.
How much short interest is there in Halozyme Therapeutics Inc?
A steep rise in short interest was recorded in Halozyme Therapeutics Inc stocks on 2024-10-31, growing by 0.39 million shares to a total of 10.25 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 9.85 million shares. There was a rise of 3.85%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on July 24, 2023 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $61 price target.
